Human plasma‐derived alpha(1)‐proteinase inhibitor in patients with new‐onset type 1 diabetes mellitus: A randomized, placebo‐controlled proof‐of‐concept study

BACKGROUND: While circulating levels of alpha(1)‐proteinase inhibitor (alpha(1)‐PI) are typically normal, antiprotease activity appears to be compromised in patients with Type 1 diabetes mellitus (T1DM). Because alpha(1)‐PI [human] (alpha(1)‐PI[h]) therapy can inhibit pro‐inflammatory mediators asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Lagarde, William H., Courtney, Kecia L., Reiner, Barry, Steinmann, Kimberly, Tsalikian, Eva, Willi, Steven M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons A/S 2020
Materias:
Type 1 Diabetes: Pathophysiology and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984376/
https://www.ncbi.nlm.nih.gov/pubmed/33244872
http://dx.doi.org/10.1111/pedi.13162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984376/
https://www.ncbi.nlm.nih.gov/pubmed/33244872
http://dx.doi.org/10.1111/pedi.13162

Ejemplares similares